IBio Common Company Leadership

IBIO Stock  USD 2.10  0.05  2.33%   
IBio Common employs about 20 people. The company is managed by 13 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 1.54 employees per reported executive. Analysis of IBio Common's management performance can provide insight into the firm performance.
Robert Kay  Chairman
Executive Chairman and CEO
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

IBio Common's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with IBio Common's future performance. Based on our forecasts, it is anticipated that IBio will maintain a workforce of about 20 employees by March 2026.
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

IBio Common Management Team Effectiveness

The company has return on total asset (ROA) of (0.2882) % which means that it has lost $0.2882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.545) %, meaning that it created substantial loss on money invested by shareholders. IBio Common's management efficiency ratios could be used to measure how well IBio Common manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of February 2026, Return On Tangible Assets is likely to drop to -1.06. In addition to that, Return On Capital Employed is likely to drop to -1.03. At this time, IBio Common's Debt To Assets are very stable compared to the past year.
As of the 2nd of February 2026, Common Stock Shares Outstanding is likely to grow to about 12.7 M, though Net Loss is likely to grow to (55.6 M). iBio Common Stock has a total of 22.49 Million outstanding shares. Over half of IBio Common's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2007-09-30
Previous Quarter
16.4 M
Current Value
53 M
Avarage Shares Outstanding
4.3 M
Quarterly Volatility
17.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as IBio Common in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of IBio Common, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

IBio Common Workforce Comparison

iBio Common Stock is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 297. IBio Common holds roughly 20.0 in number of employees claiming about 7% of equities under Health Care industry.

IBio Common Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IBio Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on IBio Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IBio Common insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
2.0
4
2
 383,100 
 84,000 
2023-09-01
0.4
2
5
 180,000 
 59,546 
2023-06-01
0.1429
1
7
 75,833 
 88,581 
2023-03-01
1.0
3
3
 217,500 
 9,189 
2022-09-01
1.3333
4
3
 5,100,000 
 13,600 
2021-12-01
8.0
8
1
 872,000 
 37,243 
2020-09-01
0.1429
1
7
 28,925,000 
 28,758,826 
2020-06-01
1.0
6
6
 1,910,642 
 271,284 
2020-03-01
3.0
6
2
 1,353,044 
 121,976 
2019-03-01
0.1733
13
75
 113,252 
 1,358,001 
2017-03-01
1.0
1
1
 1.00 
 150,000 
2016-03-01
2.0
2
1
 5,284,000 
 1,784,000 
2014-09-01
3.0
9
3
 1,610,000 
 138,710 
2014-03-01
0.0909
1
11
 100,000 
 434,342 
2013-12-01
0.5
2
4
 15,000,000 
 15,030,633 
2013-09-01
0.6
9
15
 2,692,679 
 616,419 
2012-03-01
0.0968
3
31
 235,000 
 359,890 
2010-12-01
3.0
3
1
 1,500,000 
 60,000 
2008-09-01
1.0
6
6
 469,150 
 0.00 

IBio Common Notable Stakeholders

An IBio Common stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IBio Common often face trade-offs trying to please all of them. IBio Common's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IBio Common's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert KayExecutive Chairman and CEOProfile
Lisa MiddlebrookChief OfficerProfile
Stephen KilmerInvestor OfficerProfile
Marc JDGeneral CounselProfile
Melissa BerquistVP HealthProfile
Robert LutzChief OfficerProfile
Dr DVMChief OfficerProfile
Mike JenkinsVP OperationsProfile
Thomas IIIPres CEOProfile
Randy MadduxStrategic AdvisorProfile
Kristi SarnoSenior DevelopmentProfile
Felipe DuranChief OfficerProfile
Nick DeLongVP DevelProfile
String symbol = request.getParameter("s");

About IBio Common Management Performance

The success or failure of an entity such as iBio Common Stock often depends on how effective the management is. IBio Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.01)(1.06)
Return On Capital Employed(0.98)(1.03)
Return On Assets(0.71)(0.75)
Return On Equity(1.11)(1.17)

IBio Common Workforce Analysis

Traditionally, organizations such as IBio Common use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IBio Common within its industry.

IBio Common Manpower Efficiency

Return on IBio Common Manpower

Revenue Per Employee20K
Revenue Per Executive30.8K
Net Loss Per Employee918.9K
Net Loss Per Executive1.4M
Working Capital Per Employee180.8K
Working Capital Per Executive278.1K
When determining whether iBio Common Stock offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IBio Common's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ibio Common Stock Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ibio Common Stock Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could IBio diversify its offerings? Factors like these will boost the valuation of IBio Common. Market participants price IBio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every IBio Common data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.40)
Revenue Per Share
0.038
Quarterly Revenue Growth
0.143
Return On Assets
(0.29)
Return On Equity
(0.55)
iBio Common Stock's market price often diverges from its book value, the accounting figure shown on IBio's balance sheet. Smart investors calculate IBio Common's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since IBio Common's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between IBio Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.